BriaCell reports complete, sustained resolution of brain metastasis in patient

BriaCell (BCTX) Therapeutics announced updated results from its ongoing Phase 2 study of Bria-IMT in combination with check point inhibitor in patients with advanced metastatic breast cancer. BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after greater than 18 months of treatment in the Phase 2 study. The metastatic tumor initially caused proptosis -a visibly bulging of the eye. As previously reported, the heavily pre-treated MBC patient had demonstrated a complete resolution of a temporal lobe brain metastasis and a significant response in a right orbital metastasis at 8 months, then at 11 months. The patient has now maintained both responses for more than 18 months, with no evidence of brain tumor recurrence and ongoing tumor shrinkage in the orbital lesion. This patient had failed eight prior treatment regimens, including an antibody-drug conjugate, before initiating therapy with Bria-IMT plus checkpoint inhibition. She has now completed 29 treatment cycles and has been on BriaCell’s Phase 2 study for over 21 months. Serial imaging at 8, 11, and now 20 months have confirmed no detectable disease in the right temporal lobe, along with continued response in the orbital lesion. Additionally, the patient’s tumor markers have remained markedly reduced from baseline, further supporting the sustained radiologic response.